Connect with us

CANNABIS

CBN Sleep Gummies Meet Their First Dependence Paper

A UConn mouse study found CBN fully stood in for THC and produced blocker-triggered withdrawal.

Published

on

Repeated cannabinol dosing produced THC-like cues, tolerance, and blocker-triggered withdrawal in mice, according to a University of Connecticut study in Drug and Alcohol Dependence. CBN sleep gummies are sold as a gentle hemp night aid. The paper, posted online on September 6, 2026, found that CBN fully substituted for THC in a discrimination test.

Congress has already rewritten the federal hemp definition so cannabinoids with THC-like effects can count against a tiny per-container cap. Health and Human Services has not issued that similar-effects list. This mouse result is now sitting in the file.

Tolerance, Cross-Tolerance, and a THC-Like Cue

Lead author Olivia Vanegas, who completed her Ph.D. at UConn in 2026, ran the work with Steven Kinsey, a professor in UConn’s Elisabeth DeLuca School of Nursing, Julie A. Marusich of RTI International, and chemists J. Maturano and D. Sarlah. Adult C57BL/6 mice received CBN twice daily for five days and were scored on the tetrad, a standard set of cannabis-like effects. The November 2026 issue carries the paper as article 113341 in volume 288.

Mice showed tolerance to CBN-induced catalepsy, a frozen rigid posture, to its pain-relief effect, and to the drop in body temperature. A synthetic CB1/CB2 agonist, WIN 55,212-2, then did less in those same animals, which is cross-tolerance. A separate group trained to tell THC from a blank vehicle treated CBN as the same internal cue. CBN plus THC also weakened THC’s cue, a pattern often seen with a partial agonist sitting on the same receptor.

WHAT THE MOUSE ASSAYS SHOWED

Assay Finding
Tetrad after repeated CBN Tolerance to catalepsy, pain relief, and hypothermia
WIN 55,212-2 after CBN Cannabis-like effects attenuated (cross-tolerance)
Rimonabant on day 6 Head twitches, paw tremors, more struggling
THC discrimination CBN fully substituted for THC

The RTI abstract states that repeated CBN induces tolerance and physical dependence and that CBN reduces THC’s psychoactive effects. Rimonabant, a CB1 blocker, cut THC’s cue more than CBN’s at the dose they tested, so the CBN signal was harder to knock down.

The Withdrawal Came After a Receptor Blocker

On the sixth day the team did not simply skip a dose and watch. They gave rimonabant, the classic way labs pull cannabinoid withdrawal into the open, because spontaneous cannabinoid withdrawal in mice is often faint. Head twitches and paw tremors showed up, and the animals struggled more in a tail-suspension test. Those motions are the rodent version of the shakes, not a person skipping a gummy.

University materials on the project still described CBN as less psychoactive than THC, then warned that a milder high is not the same as a lower dependence risk. Kinsey put the marketing problem in plain language.

CBN is everywhere right now. Gummies, tinctures, capsules, and it’s marketed as a safe, herbal sleep supplement. Our findings suggest consumers should be aware repeated use may carry risks.

Steven Kinsey, professor, UConn Elisabeth DeLuca School of Nursing

Vanegas said therapeutic claims about minor cannabinoids have run far ahead of repeated-use data. CBN is an oxidation product of THC that occurs in the plant in small amounts. Commercial sleep products concentrate it, often by converting other hemp cannabinoids, and sell the result next to melatonin.

10 to 20 mg Is Already a Typical Gummy

The mouse paper does not list a human milligram match, and no open abstract gives the lab’s mg/kg doses. What is on the shelf is not a mystery. Labels on common CBN sleep gummies cluster at 10 to 20 mg per piece. Charlotte’s Web Stay Asleep lists 20 mg of CBN with no CBD, THC, or melatonin. Some isolate gummies list 50 mg. An older 2021 review of the category found many sleep SKUs at 5 mg or less, so the aisle has moved up.

WHAT IS ON A TYPICAL LABEL

  • Common range: Most CBN sleep gummies list 10 to 20 mg per piece, and brands tell new users to start with a half piece.
  • CBN-only SKU: Charlotte’s Web Stay Asleep is labeled at 20 mg of CBN with no CBD, THC, or melatonin.
  • High-isolate SKUs: Some isolate gummies list 50 mg, a dose well above the 20 mg used in the only sizable human sleep trial.
  • Older baseline: A 2021 review found many sleep products at 5 mg of CBN or less, before the category pushed higher.

That 20 mg figure is also the dose in the first placebo-controlled human CBN sleep trial. It is a nightly ritual dose, not a lab curiosity, which is why a five-day mouse dependence protocol is landing on a product people already take in a row.

The Only Placebo-Controlled Sleep Trial Lasted a Week

Marcel O. Bonn-Miller and colleagues ran a remote trial from May to November 2022 in adults 18 to 55 who rated their sleep as poor or very poor. People took placebo, 20 mg CBN, or 20 mg CBN plus 10, 20, or 100 mg CBD for seven nights. The 2024 paper in Experimental and Clinical Psychopharmacology was the first placebo-controlled CBN sleep study. It was not a dependence study, and a week is not a long enough window to test one.

THE 20 MG, SEVEN-NIGHT SCORECARD

  • Sample: 293 adults in the modified intent-to-treat analysis, randomized across five arms.
  • Primary score: Sleep quality versus placebo, odds ratio 2.26 (95% CI 0.93 to 5.52), p =.082, which missed the usual cutoff.
  • Awakenings: 0.5 fewer awakenings per night versus placebo (95% CI -0.96 to -0.05), p =.025.
  • Disturbance: Sleep-disturbance score 1.36 points lower (95% CI -2.59 to -0.14), p =.023, with no change in time to fall asleep, wake after sleep onset, or next-day fatigue.

The trial found that 20 mg CBN reduced nighttime awakenings and overall sleep disturbance, while the main sleep-quality rating did not clear statistical significance. Adding CBD did not help and, in the authors’ reading, may have blunted CBN. That is a thin human benefit stacked against a mouse CB1 signal, and it is the entire controlled sleep file the gummy aisle is standing on.

Why the 0.4-Milligram Cap Now Has a Scientific Test

The 2018 Farm Bill defined hemp as cannabis at or below 0.3 percent delta-9 THC by dry weight and left finished consumer products in a gray zone the Food and Drug Administration never fully mapped. CBN rode that opening as a “non-intoxicating” sleep extra. Public Law 119-37, enacted November 12, 2025, rewrote the definition around total tetrahydrocannabinols, including THCA, and added a second pile: cannabinoids that have similar effects to THC, or are marketed that way, as determined by the HHS secretary.

WHAT THE AMENDED HEMP STATUTE CHANGES

  • The plant test: Hemp is measured by total tetrahydrocannabinols, including THCA, at or below 0.3 percent dry weight, not delta-9 alone.
  • The bottle cap: Final hemp-derived cannabinoid products may not exceed 0.4 milligrams combined total per container of total THC plus any similar-effects cannabinoids HHS names.
  • Outside-the-plant CBN: Cannabinoids made outside the plant, even if the plant can make them, are excluded from hemp, which is a live issue for converted CBN isolate.
  • The missed list: The law told FDA, within 90 days of enactment, to publish lists of cannabinoids with similar effects as THC-class compounds.

Ninety days from November 12, 2025, was February 10, 2026. A Congressional Research Service update dated September 28, 2026, said those lists had not been published. Legal advisories in October 2026 described a staged rollout, with some synthetic exclusions in November 2026 and the 0.4 milligrams cap in December 2026.

THE CLOCK ON THE HEMP REWRITE

  1. December 20, 2018: The Farm Bill sets hemp at 0.3 percent delta-9 THC and opens interstate hemp commerce.
  2. November 12, 2025: Public Law 119-37 rewrites hemp around total THC and a similar-effects test.
  3. February 10, 2026: FDA’s 90-day deadline to publish the cannabinoid lists passes unmet.
  4. September 6, 2026: The UConn CBN paper posts online, with full substitution for THC.
  5. December 2026: The 0.4-milligram per-container cap is scheduled to apply after a later delay of the original one-year clock.

If HHS later puts CBN on the similar-effects list, a 10 mg gummy is already many times the legal bottle cap. Full substitution in a THC discrimination assay is the exact kind of evidence that clause was written to catch. The statute also counts cannabinoids “marketed to have similar effects,” and CBN is marketed as a night sedative. Converted isolate could fall out of hemp even if HHS never names CBN, because much commercial CBN is manufactured outside the plant.

Inflammation Dropped, and Infection Defense Went With It

University materials on the Kinsey group’s CBN work also describe anti-inflammatory effects at lower doses that did not produce psychoactive signs in mice. During a simulated bacterial challenge, CBN weakened the animals’ ability to mount a defense, the kind of trade that shows up when a compound turns down immune signaling. That finding is not in the dependence-paper abstract, and it should not be folded into the tetrad results. It is part of the same lab’s case that CBN is pharmacologically busy at more than one system.

Kinsey has said CBN may still have therapeutic value. A compound that calms inflammation at a low dose and mimics THC at a higher one is a drug-development problem, not a gummy-aisle slogan. No published human study in this file maps those immune effects onto a 10 to 20 mg nightly chew, and the Bonn-Miller trial did not report infection outcomes.

The Mouse Data Stops Short of Human Addiction

Physical dependence in this design means the CB1 system adapted and a blocker made that adaptation visible. It is not the same as addiction, which includes craving, lost control, and harm. The experiment cannot say how often either happens in people taking labeled sleep-gummy doses, and the authors do not claim it can. Spontaneous withdrawal after a missed gummy was not the test they ran.

Melatonin, the product CBN is often parked beside, does not act at CB1. CBN does, and in these mice it was close enough to THC that animals trained on THC treated it as the same cue. That is the fact the sleep aisle did not have when the Farm Bill opened the door. It is also the fact HHS still has not answered in a similar-effects list, while 10 to 20 mg gummies remain on sale as an herbal night aid.

Kinsey’s closer in the university statement was “buyer beware,” until dosing and long-term effects are clearer. The paper is now the strongest repeated-use evidence on a product built for nightly use. The list that would decide whether those milligrams even count as hemp has not been published.

Disclaimer: This article is news reporting and analysis of a published mouse study, a human sleep trial, and federal hemp statutes. It is informational only and is not medical advice, a diagnosis, or a recommendation to start, stop, or change any cannabinoid, sleep aid, or supplement. Readers should talk with a licensed physician or pharmacist who knows their history before using CBN products, especially with other sedatives or during illness. Figures, product labels, and legal statuses come from the papers and statutes cited here and can change as new trials, lists, or rules appear.

Harry is the editor and lead writer of MMJ GAZETTE, an independent title on medical cannabis that he owns and runs, covering the science, patient programs, products and the laws that decide who can use them. Ten years of journalism sit behind the site, the first of them as a reporter and the later ones as an editor, with medical cannabis taking up most of that decade. His reporting is built on the clinical literature and the rulebooks: peer-reviewed trials and systematic reviews, trial registry entries, dosing and safety data, the enabling statutes and program rules for each medical scheme, and the guidance issued to prescribers. Study results are reported with their sample size, comparator and confidence interval, each checked against the paper itself before publication, and a claim that outruns the evidence is cut. When an error is found, the article is corrected and a dated note records the change, in line with the site's public corrections policy. Medical cannabis remains illegal in many places and the articles are not treatment advice, so patients should talk with a clinician who knows their history. Reader questions go to support@mmjgazette.com.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending